Mucormycosis: A Rare disease to Notifiable Disease.
India
Mucorales
Mucormycosis
Notifiable disease
Journal
Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
ISSN: 1678-4405
Titre abrégé: Braz J Microbiol
Pays: Brazil
ID NLM: 101095924
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
10
05
2023
accepted:
21
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Mucormycosis is the third most frequent invasive mycosis, following candidiasis and aspergillosis. It is frequently neglected due to its rare occurrence; but recently attend the status of notifiable disease due to its higher incidence in both developed and developing nations. India has received global notice since its estimated instances were greater than the global estimated figures. Mucormycosis has several clinical manifestations, including rhino-orbital-cerebral (ROCM), pulmonary, gastrointestinal, cutaneous, renal, and diffuse Mucormycosis. ROCM is the most frequent clinical manifestation in India, although pulmonary mucormycosis is prevalent worldwide. This review also discusses host defenses, pre disposing risk factors and fungal virulence factors that impair host's ability to prevent fungus invasion and disease establishment. The diagnosis of the disease depends on clinical interventions, histological or microbiological procedures along with molecular methods to obtain timely results. But there are still unmet challenges for rapid diagnosis of the disease. Treatment of the disease is achieved by multimodal approaches such as reversal of underlying predisposing factors, rapid administration of antifungals in optimal doses and surgical procedures to remove infected tissues. Liposomal Amphotericin B, Posaconazole and Isavuconazoles are preferred as the first line of treatment procedures. clinical trials. Different studies have improved the existing drug and under clinical trials while several studies predicted the new potential targets as CotH and Ftr1 as shown in infection and in vitro models. Therefore, current scenario demands a multidisciplinary approach is needed to investigate the prevalence, pathogenesis which is highly important for the advancement of rapid diagnosis and effective treatment.
Identifiants
pubmed: 38561499
doi: 10.1007/s42770-024-01315-z
pii: 10.1007/s42770-024-01315-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.
Références
World Health Organization. COVID-19 Weekly Epidemiological Update. World Heal Organ. 2022;(August):1–33. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update
Bardi T, Pintado V, Gomez-Rojo M et al (2021) Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis 40(3):495–502. https://doi.org/10.1007/s10096-020-04142-w
doi: 10.1007/s10096-020-04142-w
pubmed: 33389263
pmcid: 7778834
Kumar M, Sarma DK, Shubham S et al (2021) Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr Res Microb Sci 2:100057. https://doi.org/10.1016/j.crmicr.2021.100057
doi: 10.1016/j.crmicr.2021.100057
pubmed: 34396355
pmcid: 8349419
Rocha ICN, Hasan MM, Goyal S et al (2021) COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India. Trop Med Int Heal 26(9):1016–1018. https://doi.org/10.1111/tmi.13641
doi: 10.1111/tmi.13641
Prakash H, Chakrabarti A (2019) Global epidemiology of mucormycosis. J Fungi. 5(1). https://doi.org/10.3390/jof5010026
Skiada A, Pavleas I, Drogari-Apiranthitou M (2020) Epidemiology and diagnosis of mucormycosis: An update. J Fungi 6(4):1–20. https://doi.org/10.3390/jof6040265
doi: 10.3390/jof6040265
Prakash H, Ghosh AK, Rudramurthy SM et al (2019) A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol 57(4):395–402. https://doi.org/10.1093/mmy/myy060
doi: 10.1093/mmy/myy060
pubmed: 30085158
Jeong W, Keighley C, Wolfe R et al (2019) The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 25(1):26–34. https://doi.org/10.1016/j.cmi.2018.07.011
doi: 10.1016/j.cmi.2018.07.011
pubmed: 30036666
Lewis RE, Cahyame-Zuniga L, Leventakos K et al (2013) Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: A 20-year autopsy study. Mycoses 56(6):638–645. https://doi.org/10.1111/myc.12081
doi: 10.1111/myc.12081
pubmed: 23551865
Kontoyiannis DP, Yang H, Song J et al (2016) Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect Dis 16(1):1–6. https://doi.org/10.1186/s12879-016-2023-z
doi: 10.1186/s12879-016-2023-z
Zilberberg MD, Shorr AF, Huang H, Chaudhari P, Paly VF, Menzin J (2014) Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: A retrospective analysis of US hospital discharge data. BMC Infect Dis 14(1):1–10. https://doi.org/10.1186/1471-2334-14-310
doi: 10.1186/1471-2334-14-310
Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea I, Bouza E (2007) Impact of zygomycosis on microbiology workload: A survey study in Spain. J Clin Microbiol 45(6):2051–2053. https://doi.org/10.1128/JCM.02473-06
doi: 10.1128/JCM.02473-06
pubmed: 17392438
pmcid: 1933097
Guinea J, Escribano P, Vena A et al (2017) Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS ONE 12(6):1–10. https://doi.org/10.1371/journal.pone.0179136
doi: 10.1371/journal.pone.0179136
Bitar D, Van Cauteren D, Lanternier F et al (2009) Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 15(9):1395–1401. https://doi.org/10.3201/eid1509.090334
doi: 10.3201/eid1509.090334
pubmed: 19788806
pmcid: 2819884
Ambrosioni J, Bouchuiguir-Wafa K, Garbino J (2010) Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors. Int J Infect Dis 14(SUPPL. 3):e100–e103. https://doi.org/10.1016/j.ijid.2009.11.024
doi: 10.1016/j.ijid.2009.11.024
pubmed: 20335060
Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K (2010) Increasing incidence of Mucormycosis in university hospital. Belgium Emerg Infect Dis 16(9):1456–1458. https://doi.org/10.3201/eid1609.100276
doi: 10.3201/eid1609.100276
pubmed: 20735932
Dolatabadi S, Ahmadi B, Rezaei-Matehkolaei A et al (2018) Mucormycosis in Iran: A six-year retrospective experience. J Mycol Med 28(2):269–273. https://doi.org/10.1016/j.mycmed.2018.02.014
doi: 10.1016/j.mycmed.2018.02.014
pubmed: 29545123
Ueno R, Nishimura S, Fujimoto G, Ainiwaer D (2021) The disease burden of mucormycosis in Japan: results from a systematic literature review and retrospective database study. Curr Med Res Opin 37(2):253–260. https://doi.org/10.1080/03007995.2020.1846510
doi: 10.1080/03007995.2020.1846510
pubmed: 33143482
Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O (2012) Diabetes and mucormycosis: A complex interplay. Diabetes Metab 38(3):193–204. https://doi.org/10.1016/j.diabet.2012.01.002
doi: 10.1016/j.diabet.2012.01.002
pubmed: 22386924
Chakrabarti A, Singh R (2014) Mucormycosis in India: Unique features. Mycoses 57(s3):85–90. https://doi.org/10.1111/myc.12243
doi: 10.1111/myc.12243
pubmed: 25187095
Xess I, Mohapatra S, Shivaprakash MR et al (2012) Evidence implicating Thamnostylum lucknowense as an etiological agent of rhino-orbital mucormycosis. J Clin Microbiol 50(4):1491–1494. https://doi.org/10.1128/JCM.06611-11
doi: 10.1128/JCM.06611-11
pubmed: 22301030
pmcid: 3318503
Prakash H, Singh S, Rudramurthy SM et al (2020) An aero mycological analysis of Mucormycetes in indoor and outdoor environments of northern India. Med Mycol 58(1):118–123. https://doi.org/10.1093/mmy/myz031
doi: 10.1093/mmy/myz031
pubmed: 30980083
Pamidimukkala U, Sudhaharan S, Kancharla A et al (2021) Mucormycosis due to Apophysomyces species complex- 25 years’ experience at a tertiary care hospital in southern India. Med Mycol 58(4):425–433. https://doi.org/10.1093/MMY/MYZ081
doi: 10.1093/MMY/MYZ081
Sahu RK, Salem-Bekhit MM, Bhattacharjee B, et al. (2021) Mucormycosis in indian covid-19 patients: Insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics. 10(9). https://doi.org/10.3390/antibiotics10091079
Ghazi BK, Rackimuthu S, Wara UU et al (2021) Rampant increase in cases of mucormycosis in India and Pakistan: A serious cause for concern during the ongoing COVID-19 pandemic. Am J Trop Med Hyg 105(5):1144–1147. https://doi.org/10.4269/ajtmh.21-0608
doi: 10.4269/ajtmh.21-0608
pubmed: 34460426
pmcid: 8592182
Stone N, Gupta N, Schwartz I (2021) Mucormycosis: time to address this deadly fungal infection. The Lancet Microbe 2(8):e343–e344. https://doi.org/10.1016/S2666-5247(21)00148-8
doi: 10.1016/S2666-5247(21)00148-8
pubmed: 35544192
Yasmin F, Najeeb H, Siddiqui SA, Ochani RK (2022) Mucormycosis and COVID-19: Double trouble for India? J Glob Health 12:3–7. https://doi.org/10.7189/jogh.12-03001
doi: 10.7189/jogh.12-03001
Kwon-Chung KJ (2012) Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin Infect Dis. 54(SUPPL. 1). https://doi.org/10.1093/cid/cir864
Borkar SG (2021) Mucormycosis: A Surge in Mucorales Fungal Infection in Post – Covid Patients in Indian States and Insight into Known and Unknown Factors. Int J Glob Heal 1(3):26–60. https://doi.org/10.14302/issn.2693-1176.ijgh-21-3907
doi: 10.14302/issn.2693-1176.ijgh-21-3907
Walther G, Wagner L, Kurzai O. (2019) Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J Fungi. 5(4). https://doi.org/10.3390/jof5040106
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP (2012) Pathogenesis of mucormycosis. Clin Infect Dis 54(SUPPL. 1):1–7. https://doi.org/10.1093/cid/cir865
doi: 10.1093/cid/cir865
Petraitis V, Petraitiene R, Antachopoulos C et al (2013) Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: Correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. Med Mycol 51(1):72–82. https://doi.org/10.3109/13693786.2012.690107
doi: 10.3109/13693786.2012.690107
pubmed: 22686246
Nicolás FE, Murcia L, Navarro E, Navarro-Mendoza MI, Pérez-Arques C, Garre V (2020) Mucorales species and macrophages. J Fungi 6(2):1–12. https://doi.org/10.3390/jof6020094
doi: 10.3390/jof6020094
Kaerger K, Schwartze VU, Dolatabadi S et al (2015) Adaptation to thermotolerance in Rhizopus coincides with virulence as revealed by avian and invertebrate infection models, phylogeny, physiological and metabolic flexibility. Virulence 6(4):395–403. https://doi.org/10.1080/21505594.2015.1029219
doi: 10.1080/21505594.2015.1029219
pubmed: 26065324
pmcid: 4604701
Soare AY, Watkins TN, Bruno VM (2020) Understanding Mucormycoses in the Age of “omics.” Front Genet 11(June):1–11. https://doi.org/10.3389/fgene.2020.00699
doi: 10.3389/fgene.2020.00699
Ibrahim AS, Gebremariam T, Lin L et al (2010) The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 77(3):587–604. https://doi.org/10.1111/j.1365-2958.2010.07234.x
doi: 10.1111/j.1365-2958.2010.07234.x
pubmed: 20545847
pmcid: 2909342
Laaberki MH, Dworkin J (2008) Role of spore coat proteins in the resistance of Bacillus subtilis spores to Caenorhabditis elegans predation. J Bacteriol 190(18):6197–6203. https://doi.org/10.1128/JB.00623-08
doi: 10.1128/JB.00623-08
pubmed: 18586932
pmcid: 2546783
Chibucos MC, Soliman S, Gebremariam T et al (2016) An integrated genomic and transcriptomic survey of mucormycosis-causing fungi. Nat Commun 7:1–11. https://doi.org/10.1038/ncomms12218
doi: 10.1038/ncomms12218
Lax C, Pérez‐arques C, Navarro‐mendoza MI, et al. (2020) Genes, pathways, and mechanisms involved in the virulence of mucorales. Genes (Basel). 11(3). https://doi.org/10.3390/genes11030317
Gebremariam T, Alkhazraji S, Soliman SSM et al (2019) Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. Sci Adv 5(6):1–15. https://doi.org/10.1126/sciadv.aaw1327
doi: 10.1126/sciadv.aaw1327
Liu H, Lee MJ, Solis NV et al (2016) Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion. Nat Microbiol 2(November):1–10. https://doi.org/10.1038/nmicrobiol.2016.211
doi: 10.1038/nmicrobiol.2016.211
Baldin C, Ibrahim AS (2017) Molecular mechanisms of mucormycosis—The bitter and the sweet. PLoS Pathog 13(8):1–9. https://doi.org/10.1371/journal.ppat.1006408
doi: 10.1371/journal.ppat.1006408
Binder U, Maurer E, Lass-Flörl C (2014) Mucormycosis - from the pathogens to the disease. Clin Microbiol Infect 20(6):60–66. https://doi.org/10.1111/1469-0691.12566
doi: 10.1111/1469-0691.12566
pubmed: 24476149
Prakash H, Rudramurthy SM, Gandham PS et al (2017) Apophysomyces variabilis: Draft genome sequence and comparison of predictive virulence determinants with other medically important Mucorales. BMC Genomics 18(1):1–13. https://doi.org/10.1186/s12864-017-4136-1
doi: 10.1186/s12864-017-4136-1
Hassan MIA, Voigt K (2019) Pathogenicity patterns of mucormycosis: Epidemiology, interaction with immune cells and virulence factors. Med Mycol 57:S245–S256. https://doi.org/10.1093/mmy/myz011
doi: 10.1093/mmy/myz011
pubmed: 30816980
pmcid: 6394756
Sugui JA, Christensen JA, Bennett JE, Zelazny AM, Kwon-Chung KJ (2011) Hematogenously disseminated skin disease caused by Mucor velutinosus in a patient with acute myeloid leukemia. J Clin Microbiol 49(7):2728–2732. https://doi.org/10.1128/JCM.00387-11
doi: 10.1128/JCM.00387-11
pubmed: 21543575
pmcid: 3147817
Shelburne SA, Ajami NJ, Chibucos MC et al (2015) Implementation of a pan-genomic approach to investigate holobiont-infecting microbe interaction: A case report of a leukemic patient with invasive mucormycosis. PLoS ONE 10(11):1–17. https://doi.org/10.1371/journal.pone.0139851
doi: 10.1371/journal.pone.0139851
Lee SC, Li A, Calo S et al (2015) Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides. Mol Microbiol 97(5):844–865. https://doi.org/10.1111/mmi.13071
doi: 10.1111/mmi.13071
pubmed: 26010100
pmcid: 4633022
Vellanki S, Billmyre RB, Lorenzen A, et al. (2020) A novel resistance pathway for calcineurin inhibitors in the human-pathogenic mucorales mucor circinelloides. MBio. 11(1). https://doi.org/10.1128/mBio.02949-19
Lee SC, Li A, Calo S, Heitman J. (2013) Calcineurin Plays Key Roles in the Dimorphic Transition and Virulence of the Human Pathogenic Zygomycete Mucor circinelloides. PLoS Pathog. 9(9). https://doi.org/10.1371/journal.ppat.1003625
Trieu TA, Navarro-Mendoza MI, Pérez-Arques C et al (2017) RNAi-Based Functional Genomics Identifies New Virulence Determinants in Mucormycosis. PLoS Pathog 13(1):1–26. https://doi.org/10.1371/journal.ppat.1006150
doi: 10.1371/journal.ppat.1006150
Papon N, Naglik JR, Hube B, Goldman GH (2021) Fungal pathogenesis: A new venom. Curr Biol 31(8):R391–R394. https://doi.org/10.1016/j.cub.2021.03.015
doi: 10.1016/j.cub.2021.03.015
pubmed: 33905698
Soliman SSM, Baldin C, Gu Y et al (2021) Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis. Nat Microbiol 6(3):313–326. https://doi.org/10.1038/s41564-020-00837-0
doi: 10.1038/s41564-020-00837-0
pubmed: 33462434
pmcid: 7914224
Pérez-Arques C, Navarro-Mendoza MI, Murcia L, et al. (2019) Mucor circinelloides thrives inside the phagosome through an atf-mediated germination pathway. MBio. 10(1). https://doi.org/10.1128/mBio.02765-18
Navarro-Mendoza MI, Pérez-Arques C, Murcia L et al (2018) Components of a new gene family of ferroxidases involved in virulence are functionally specialized in fungal dimorphism. Sci Rep 8(1):1–13. https://doi.org/10.1038/s41598-018-26051-x
doi: 10.1038/s41598-018-26051-x
Gebremariam T, Liu M, Luo G et al (2014) CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest 124(1):237–250. https://doi.org/10.1172/JCI71349
doi: 10.1172/JCI71349
pubmed: 24355926
Patiño-Medina JA, Maldonado-Herrera G, Pérez-Arques C et al (2018) Control of morphology and virulence by ADP-ribosylation factors (Arf) in Mucor circinelloides. Curr Genet 64(4):853–869. https://doi.org/10.1007/s00294-017-0798-0
doi: 10.1007/s00294-017-0798-0
pubmed: 29264641
Ribes JA, Vanover-Sams CL, Baker DJ (2000) Zygomycetes in human disease. Clin Microbiol Rev 13(2):236–301. https://doi.org/10.1128/CMR.13.2.236-301.2000
doi: 10.1128/CMR.13.2.236-301.2000
pubmed: 10756000
pmcid: 100153
Li Z, Lu G, Meng G. (2019) Pathogenic fungal infection in the lung. Front Immunol. 10(JUL):1–20. https://doi.org/10.3389/fimmu.2019.01524
Radotra B, Challa S (2022) Pathogenesis and Pathology of COVID-Associated Mucormycosis: What Is New and Why. Curr Fungal Infect Rep 16(4):206–220. https://doi.org/10.1007/s12281-022-00443-z
doi: 10.1007/s12281-022-00443-z
pubmed: 36193101
pmcid: 9520103
Challa S (2019) Mucormycosis: Pathogenesis and Pathology. Curr Fungal Infect Rep 13(1):11–20. https://doi.org/10.1007/s12281-019-0337-1
doi: 10.1007/s12281-019-0337-1
Joseph A. Lemire; Joe J. Harrison & Raymond J. Turner. (2013) Antimicrobial activity of metals_ mechanisms, molecular targets and applications _ Nature Reviews Microbiology _ Nature Publishing Group. 11(June). https://doi.org/10.1038/nrmicro3028
Petrikkos G, Tsioutis C (2018) Recent Advances in the Pathogenesis of Mucormycoses. Clin Ther 40(6):894–902. https://doi.org/10.1016/j.clinthera.2018.03.009
doi: 10.1016/j.clinthera.2018.03.009
pubmed: 29631910
Jorens PG, Boelaert JR, Halloy V, Zamora R, Schneider YJ, Herman AG (1995) Human and rat macrophages mediate fungistatic activity against Rhizopus species differently: In vitro and ex vivo studies. Infect Immun 63(11):4489–4494. https://doi.org/10.1128/iai.63.11.4489-4494.1995
doi: 10.1128/iai.63.11.4489-4494.1995
pubmed: 7591090
pmcid: 173639
Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP (2008) Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 52(2):722–724. https://doi.org/10.1128/AAC.01136-07
doi: 10.1128/AAC.01136-07
pubmed: 18025115
Posch W, Wilflingseder D, Lass-Flörl C (2020) Immunotherapy as an Antifungal Strategy in Immune Compromised Hosts. Curr Clin Microbiol Reports 7(3):57–66. https://doi.org/10.1007/s40588-020-00141-9
doi: 10.1007/s40588-020-00141-9
Pushparaj K, Kuchi Bhotla H, Arumugam VA et al (2022) Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets - Magnifying global pandemic grieve and catastrophe begins. Sci Total Environ 805:150355. https://doi.org/10.1016/j.scitotenv.2021.150355
doi: 10.1016/j.scitotenv.2021.150355
pubmed: 34818767
Kovalenko M, Rönnstrand L, Heldin CH et al (1997) Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 36(21):6260–6269. https://doi.org/10.1021/bi962553l
doi: 10.1021/bi962553l
pubmed: 9174341
Watkins TN, Gebremariam T, Swidergall M et al (2018) Inhibition of EGFR signaling protects from mucormycosis. MBio 9(4):1–13. https://doi.org/10.1128/mBio.01384-18
doi: 10.1128/mBio.01384-18
Liu M, Spellberg B, Phan QT et al (2010) The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 120(6):1914–1924. https://doi.org/10.1172/JCI42164
doi: 10.1172/JCI42164
pubmed: 20484814
pmcid: 2877958
Lugito NPH, Cucunawangsih C (2021) How Does Mucorales Benefit from the Dysregulated Iron Homeostasis During SARS-CoV-2 Infection? Mycopathologia 186(6):877–882. https://doi.org/10.1007/s11046-021-00594-6
doi: 10.1007/s11046-021-00594-6
pubmed: 34623597
pmcid: 8497685
Alqarihi A, Gebremariam T, Gu Y et al (2020) GRP78 and integrins play different roles in host cell invasion during mucormycosis. MBio 11(3):1–18. https://doi.org/10.1128/mBio.01087-20
doi: 10.1128/mBio.01087-20
Lin L, Gebremariam T, Ibrahim AS. (2015) Passive immunization with CotH3 antibodies protects neutropenic mice from lethal mucormycosis through enhancing macrophage killing (MPF6P.660). J Immunol. 194(1_Supplement):202.18–202.18. https://doi.org/10.4049/jimmunol.194.supp.202.18
Galaris D, Barbouti A, Pantopoulos K (2019) Iron homeostasis and oxidative stress: An intimate relationship. Biochim Biophys Acta - Mol Cell Res 1866(12):118535. https://doi.org/10.1016/j.bbamcr.2019.118535
doi: 10.1016/j.bbamcr.2019.118535
pubmed: 31446062
Ibrahim AS, Spellberg B, Edwards J (2008) Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21(6):620–625. https://doi.org/10.1097/QCO.0b013e3283165fd1
doi: 10.1097/QCO.0b013e3283165fd1
pubmed: 18978530
pmcid: 2773686
Symeonidis AS (2009) The role of iron and iron chelators in zygomycosis. Clin Microbiol Infect 15(SUPPL. 5):26–32. https://doi.org/10.1111/j.1469-0691.2009.02976.x
doi: 10.1111/j.1469-0691.2009.02976.x
pubmed: 19754753
Shirazi F, Kontoyiannis DP, Ibrahim AS (2015) Iron starvation induces apoptosis in rhizopus oryzae in vitro. Virulence 6(2):121–126. https://doi.org/10.1080/21505594.2015.1009732
doi: 10.1080/21505594.2015.1009732
pubmed: 25830548
pmcid: 4601319
Howard DH (1999) Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev 12(3):394–404. https://doi.org/10.1128/cmr.12.3.394
doi: 10.1128/cmr.12.3.394
pubmed: 10398672
pmcid: 100245
Tabassum T, Araf Y, Moin AT, Rahaman TI, Hosen MJ (2022) COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression. Mol Biol Rep 49(1):747–754. https://doi.org/10.1007/s11033-021-06862-4
doi: 10.1007/s11033-021-06862-4
pubmed: 34709573
Larcher G, Dias M, Razafimandimby B, Bomal D, Bouchara JP (2013) Siderophore Production by Pathogenic Mucorales and Uptake of Deferoxamine B. Mycopathologia 176(5–6):319–328. https://doi.org/10.1007/s11046-013-9693-5
doi: 10.1007/s11046-013-9693-5
pubmed: 23982284
Alejandre-Castañeda V, Patiño-Medina JA, Valle-Maldonado MI et al (2022) Secretion of the siderophore rhizoferrin is regulated by the cAMP-PKA pathway and is involved in the virulence of Mucor lusitanicus. Sci Rep 12(1):1–16. https://doi.org/10.1038/s41598-022-14515-0
doi: 10.1038/s41598-022-14515-0
Khanna M, Challa S, Kabeil AS, et al. (2021) Risk of Mucormycosis in Diabetes Mellitus: A Systematic Review. Cureus. 13(10). https://doi.org/10.7759/cureus.18827
Ibrahim AS, Gebermariam T, Fu Y et al (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117(9):2649–2657. https://doi.org/10.1172/JCI32338
doi: 10.1172/JCI32338
pubmed: 17786247
pmcid: 1957543
Ponnaiah M, Ganesan S, Bhatnagar T, et al. (2022) Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India. PLoS One. 17(8 August):1–17. https://doi.org/10.1371/journal.pone.0272042
Fouad YA, Abdelaziz TT, Askoura A et al (2021) Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic. Front Med 8(May):1–6. https://doi.org/10.3389/fmed.2021.645270
doi: 10.3389/fmed.2021.645270
Pai V, Sansi R, Kharche R, Bandili SC, Pai B. (2021) Rhino-orbito-cerebral Mucormycosis: Pictorial Review. Insights Imaging. 12(1). https://doi.org/10.1186/s13244-021-01109-z
Spellberg B, Edwards J, Ibrahim A (2005) Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 18(3):556–569. https://doi.org/10.1128/CMR.18.3.556-569.2005
doi: 10.1128/CMR.18.3.556-569.2005
pubmed: 16020690
pmcid: 1195964
Luo Z, Zhang L (2017) Diagnosis and treatment of pulmonary mucormycosis: A case report. Exp Ther Med 14(4):3788–3791. https://doi.org/10.3892/etm.2017.4986
doi: 10.3892/etm.2017.4986
pubmed: 29042980
pmcid: 5639346
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP (2012) Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54(SUPPL. 1):23–34. https://doi.org/10.1093/cid/cir866
doi: 10.1093/cid/cir866
Castrejón-Pérez AD, Miranda I, Welsh O, Welsh EC, Ocampo-Candiani J (2017) Cutaneous mucormycosis. An Bras Dermatol 92(3):304–311. https://doi.org/10.1590/abd1806-4841.20176614
doi: 10.1590/abd1806-4841.20176614
pubmed: 29186239
pmcid: 5514567
Naqvi H, Yousaf MN, Mills L. (2020) S3012 Gastric Mucormycosis; An Infection of Fungal Invasion Into the Gastric Mucosa in Immunocompromised Patients. Am J Gastroenterol. 115(1):S1587-S1587. https://doi.org/10.14309/01.ajg.0000714096.55092.bc
Garrido-Molina JM, Márquez-Hernández VV, Alcayde-García A et al (2021) 乳鼠心肌提取 HHS Public Access. J Hosp Infect 45(1):617–621. https://doi.org/10.1016/S1473-3099(19)30312-3.Global
doi: 10.1016/S1473-3099(19)30312-3.Global
Ponnaiyan D, Anitha C m., Prakash P s. g., et al. (2022) Mucormycosis diagnosis revisited: Current and emerging diagnostic methodologies for the invasive fungal infection (Review). Exp Ther Med. 25(1):1–6. https://doi.org/10.3892/etm.2022.11746
Sharma A, Goel A (2022) Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha) 67(3):363–387. https://doi.org/10.1007/s12223-021-00934-5
doi: 10.1007/s12223-021-00934-5
pubmed: 35220559
Afshar P, Larijani LV, Rouhanizadeh H (2018) A comparison of conventional rapid methods in diagnosis of superficial and cutaneous mycoses based on KOH, chicago sky blue 6b and calcofluor white stains. Iran J Microbiol 10(6):433–440
pubmed: 30873272
pmcid: 6414738
Lass-Flörl C (2009) Zygomycosis: Conventional laboratory diagnosis. Clin Microbiol Infect 15(SUPPL. 5):60–65. https://doi.org/10.1111/j.1469-0691.2009.02999.x
doi: 10.1111/j.1469-0691.2009.02999.x
pubmed: 19754760
Frater JL, Hall GS, Procop GW (2001) Histologic Features of Zygomycosis. Arch Pathol Lab Med 125(3):375–378. https://doi.org/10.5858/2001-125-0375-hfoz
doi: 10.5858/2001-125-0375-hfoz
pubmed: 11231486
Mansoor S, Ahmed TI, Happa K, Sultan M, Manhas S, Shamas S (2022) Spectrum of Mucormycosis Before and During COVID-19: Epidemiology, Diagnosis, and Current Therapeutic Interventions. Curr Fungal Infect Rep 16(4):131–142. https://doi.org/10.1007/s12281-022-00438-w
doi: 10.1007/s12281-022-00438-w
pubmed: 35967987
pmcid: 9364274
Dadwal SS, Kontoyiannis DP (2018) Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn 18(10):845–854. https://doi.org/10.1080/14737159.2018.1522250
doi: 10.1080/14737159.2018.1522250
pubmed: 30203997
Garre V (2022) Recent Advances and Future Directions in the Understanding of Mucormycosis. Front Cell Infect Microbiol 12(February):1–7. https://doi.org/10.3389/fcimb.2022.850581
doi: 10.3389/fcimb.2022.850581
Acosta-España JD, Voigt K. (2022) Mini Review: Risk Assessment, Clinical Manifestation, Prediction, and Prognosis of Mucormycosis: Implications for Pathogen- and Human-Derived Biomarkers. Front Microbiol. 13(June). https://doi.org/10.3389/fmicb.2022.895989
Brunet K, Rammaert B (2020) Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Med 30(3):1–6. https://doi.org/10.1016/j.mycmed.2020.101007
doi: 10.1016/j.mycmed.2020.101007
Reed C, Bryant R, Ibrahim AS et al (2008) Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47(3):364–371. https://doi.org/10.1086/589857
doi: 10.1086/589857
pubmed: 18558882
Natesan SK, Chandrasekar PH (2016) Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: Current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist 9:291–300. https://doi.org/10.2147/IDR.S102207
doi: 10.2147/IDR.S102207
pubmed: 27994475
pmcid: 5153275
Schwartz S, Cornely OA, Hamed K et al (2021) Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol 58(4):417–424. https://doi.org/10.1093/MMY/MYZ103
doi: 10.1093/MMY/MYZ103
Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR (2002) In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46(5):1581–1582. https://doi.org/10.1128/AAC.46.5.1581-1582.2002
doi: 10.1128/AAC.46.5.1581-1582.2002
pubmed: 11959605
pmcid: 127128
Zhao Y, Perlin DS (2020) Review of the novel echinocandin antifungal rezafungin: Animal studies and clinical data. J Fungi 6(4):1–9. https://doi.org/10.3390/jof6040192
doi: 10.3390/jof6040192
Rathod M, Patel JJ, Universiy P, et al. (2022) A Comprehensive Review on Mucormycosis A Comprehensive Review on Mucormycosis Dr Mrudangsinh Rathod a , Mr Jaydev Patel * a , Mr Manthan Prajapati a , Mr Madhav oza a. https://doi.org/10.35629/7781-0705883890
Shaw KJ, Ibrahim AS (2020) Fosmanogepix: A review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi 6(4):1–21. https://doi.org/10.3390/jof6040239
doi: 10.3390/jof6040239
Maurer E, Hörtnagl C, Lackner M et al (2019) Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment. Med Mycol 57(3):351–362. https://doi.org/10.1093/mmy/myy042
doi: 10.1093/mmy/myy042
pubmed: 29924357
Seif M, Kakoschke TK, Ebel F et al (2022) CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med 14(664):1–9. https://doi.org/10.1126/scitranslmed.abh1209
doi: 10.1126/scitranslmed.abh1209
Ma LJ, Ibrahim AS, Skory C, et al. (2009) Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet. 5(7). https://doi.org/10.1371/journal.pgen.1000549